What's Hot
View all perspectives
Eric Dein ejdein1
4 years ago
Good images of multicentric reticulohistiocytosis: note the DIP involvement as a tip off! TM14 @RheumNow #ACR20. https://t.co/Za4X0WTdtb
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
64 yo Indian F w/ previous dx of RA presents w/ skin lesions & arthritis (images below) in setting of high CRP, neg RF & CCP, ANA 1:80 speckled? What’s your diagnosis? Check our TM poster 14 for the answer! #ACR20 @RheumNow https://t.co/A11TDrwRga
Dr. Rachel Tate uptoTate
4 years ago
PREVENT study: SEC provided clinically meaningful improvement in back pain, morning stiffness, fatigue, & physical function in TNFi-naïve nr-axSpA pts over 52 weeks. #ABS1340 #ACR20 @RheumNow https://t.co/RugzhqbY2A https://t.co/5kaZWoYk9t
Janet Pope Janetbirdope
4 years ago
Gout ^CV events but hard to unravel as an independent risk as so many with gout have CRF, HTN, metabolic syndrome. But beware and get CV risk factors treated in gout pts abstr#950 @RheumNow @CRASCRRheum #ACR20 https://t.co/xYxE0xpCOj
Mrinalini Dey DrMiniDey
4 years ago
Some really great & informative abstracts in #ANCA #vasculitis poster session! Incl work on thyroid disease such as ab#1433. This study confirmed the association with AAV but also showed PR3-ANCA is assoc. w/ less risk for thyroid disease.
#ACR20 @RheumNow
https://t.co/bMB0o8Eylo
Richard Conway RichardPAConway
4 years ago
Dr Kronzer and @jeffsparks presenting on lifestyle and clinical risk factors for RA-ILD. Obesity, CRP >=10mg/L, poor function, and high education level appear to be risks. Also threshold pk/yr effect for smoking #ACR20 @rheumnow https://t.co/dM73lBLXVN
Sole RetamozoSole
4 years ago
Don’t forget to look for microscopic colitis in spondyloarthritis. It’ll solve many of your unsolved questions. #ACR20 poster session @RheumNow https://t.co/M7JubMtZiB
Robert B Chao, MD doctorRBC
4 years ago
Thinking about Dr. Fauci's forecast for a vaccine to be deployed early 2021. If/when it is offered, would you receive it?
@RheumNow #ACR20
Richard Conway RichardPAConway
4 years ago
Dr Egan presents 18-month data on use of anti-IL5 therapy in 13 EGPA patients. 50% reduction in steroid dose with anti-IL5. BVAS and asthma control questionnaire improved. 12 of 13 continued anti-IL5. @rheumnow #ACR20 Abstr#1427 https://t.co/qVy7Nb3OoA
Janet Pope Janetbirdope
4 years ago
Scurvy! Corkscrew hairs. Good exam question and we may still see it in the chips & sofa crowd and other poor eating habits. Learn from sailors re eating limes=limey. So have a twist of lemon or lime in your gin &tonic. If I guessed wrong oh well! @RheumNow @CRASCRRheum #ACR20 https://t.co/c8UN3bpPHC
Richard Conway RichardPAConway
4 years ago
Dr Giorgiutti and @Lupusreference present on prevalence of AAV in relation to silica exposure from quarries. Prevalence of GPA 2 fold higher in region with quarries vs city. Spatial association between quarries and GPA but not MPA/RLV. @rheumnow #ACR20 Abstr#1426 https://t.co/xHnOWCdXWe
Mrinalini Dey DrMiniDey
4 years ago
Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients with #EGPA, with a 50% reduction in #steroid dose in the study cohort.
Abs#1427 #ACR20 @RheumNow #Vasculitis
https://t.co/elr6VR7447
Richard Conway RichardPAConway
4 years ago
Dr Juge @Juge_P_A reports on prevalence of subclinical RA-ILD as identified by HRCT. At mean disease duration of 13 years 18.2% of patients had subclinical RA-ILD. @rheumnow #ACR20 Abstr#1199 https://t.co/VWKFxwFfIJ
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by @RheumNow & its Faculty.
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Poster Hall